Silo Pharma, Inc. — Director's Dealing 2021

May 17, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Silo Pharma, Inc. (SILO)
CIK: 0001514183
Period of Report: 2019-04-15

Reporting Person: Weisblum Eric (Director, CEO, CFO and President)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-06-17	Common Stock	P	57714	$0.002	Acquired	57714	Direct
2019-10-15	Common Stock	P	200	$0.38	Acquired	57914	Direct
2019-10-22	Common Stock	P	200	$0.45	Acquired	58114	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-04-15	Stock Option (right to buy)	$0.0001	A	100000	Acquired	2024-04-15	Common Stock (100000)	Direct
2019-04-15	Stock Option (right to buy)	$0.0001	A	100000	Acquired	2024-07-15	Common Stock (100000)	Direct
2019-10-15	Stock Option (right to buy)	$0.0001	A	100000	Acquired	2024-10-15	Common Stock (100000)	Direct

Footnotes

F1: The options were granted pursuant to the Employment Agreement by and between the Issuer and the Reporting Person dated April 15, 2019.

F2: The options were granted on April 15, 2019 and vested in full on July 15, 2019.